Reports Q4 revenue $116.2M, consensus $112.48M. “Our Q4 reflects continued execution of our three-pillar strategy initiated in the second quarter of 2023,” said Kevin Thornal, CEO. “The actions we have taken, including our commercial realignment, strengthening our executive team with talented and experienced leaders, the acquisition of Vyrsa Technologies(TM) to enter the sacroiliac joint fusion space, debt refinancing, and recent restructuring, among others, further position Nevro for success…We are off to a solid start as we enter 2024 and remain focused on advancing our core strategic pillars of commercial execution, market penetration and profit progress to further position our business to deliver value for all our stakeholders and achieve profitable, long-term growth.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NVRO:
- Nevro Reports Fourth-Quarter and Full-Year 2023 Financial Results
- NVRO Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Nevro price target lowered to $19 from $23 at Canaccord
- Nevro announces Carelon publication on new interventional pain management policy
- Nevro downgraded to Sector Perform from Outperform at RBC Capital
